Skip to content
Yog Pharma
Respiratory and allergyNon-sedating H1 antihistamine

Fexofenadine Hydrochloride is a non-sedating H1 antihistamine indicated for seasonal allergic rhinitis and chronic idiopathic urticaria. We supply it to US manufacturers of tablets, orally disintegrating tablets and oral suspension.

CAS153439-40-8538.1 g/molC32H40ClNO4
2D structure of Fexofenadine Hydrochloride, shown as the active moiety without counter-ion or water of hydration.

Data from PubChem (CID 63002) and FDA’s substance registry

CAS number

153439-40-8

Molecular formula

C32H40ClNO4

Molecular weight

538.1g/mol

FDA UNII

IUPAC name

2-[4-[1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid;hydrochloride

InChIKey

RRJFVPUCXDGFJB-UHFFFAOYSA-N

Appearance
White to off-white crystalline powder.
Solubility
Freely soluble in methanol and ethanol, slightly soluble in chloroform and water, and insoluble in hexane.

Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.

Worth settling with your inquiry

Exists in several polymorphic and hydrated forms. State the form you developed with.

On the US market

Reference product
AllegraNDA 020625
Approved ANDAs
15 with a marketed product
Approved forms and strengths
  • Tablet 30 mg, 60 mg, 180 mg
  • Oral suspension 30 mg/5 mL

Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.

Grade

USP or Ph. Eur. where a monograph exists, or your own specification.

Quantities

From development quantities for formulation work to commercial supply.

Packaging

To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.

Regulatory filings

US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.

Documents available with a quote

  • Specification and certificate of analysis
  • Safety data sheet
  • Method of analysis
  • DMF letter of authorization, where a US DMF is filed
  • GMP certificate and inspection history of the site
  • Residual solvents and elemental impurities statements
  • Nitrosamine risk assessment
  • TSE/BSE statement

Need something else for your QA file? Email info@yogpharma.com